Harrow (NASDAQ:HROW) Stock Price Down 4.1% - Should You Sell?

Harrow, Inc. (NASDAQ:HROW - Get Free Report) shares were down 4.1% during trading on Thursday . The stock traded as low as $33.91 and last traded at $33.94. Approximately 55,004 shares were traded during trading, a decline of 81% from the average daily volume of 292,720 shares. The stock had previously closed at $35.40.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on HROW. Lake Street Capital boosted their price objective on shares of Harrow from $45.00 to $55.00 and gave the stock a "buy" rating in a research report on Friday, October 4th. B. Riley reduced their target price on shares of Harrow from $73.00 to $69.00 and set a "buy" rating on the stock in a research note on Wednesday, December 4th. Finally, Craig Hallum raised their price objective on shares of Harrow from $45.00 to $65.00 and gave the company a "buy" rating in a research note on Friday, October 4th.

Harrow Stock Down 5.5 %

The business's 50-day moving average is $38.86 and its two-hundred day moving average is $38.64. The firm has a market capitalization of $1.19 billion, a price-to-earnings ratio of -35.61 and a beta of 0.72. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55.

Institutional Investors Weigh In On Harrow

Several hedge funds have recently bought and sold shares of the company. Brookstone Capital Management acquired a new stake in Harrow during the 4th quarter worth $275,000. JPMorgan Chase & Co. increased its holdings in shares of Harrow by 443.1% in the third quarter. JPMorgan Chase & Co. now owns 238,367 shares of the company's stock worth $10,717,000 after acquiring an additional 194,480 shares in the last quarter. Principal Financial Group Inc. acquired a new stake in shares of Harrow during the third quarter worth about $329,000. Virtu Financial LLC bought a new position in shares of Harrow during the 3rd quarter valued at about $271,000. Finally, Geode Capital Management LLC grew its position in shares of Harrow by 0.6% in the 3rd quarter. Geode Capital Management LLC now owns 722,730 shares of the company's stock valued at $32,500,000 after purchasing an additional 3,960 shares during the period. 72.76% of the stock is currently owned by institutional investors and hedge funds.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.